Byron Nash Renal Medullary Carcinoma Awareness Act of 2023
January 3, 2025
Track this bill to get notified when it advances a stage. One tap to stop, anytime.
Where This Stands
Currently in_committee. The next step in the legislative lifecycle is Floor Vote.
Version history
Only one version on file - nothing to compare yet. As later stages (committee substitute, engrossed, enrolled) are captured, the redline appears here.
View official text →The Frame
The bill initiates the legislative process to potentially allocate federal resources or mandate public health initiatives specifically targeting Renal Medullary Carcinoma awareness.
Potentially affected actors named in the source documents. Mention is not a position.
House Committee on Energy and Commerce
The committee is responsible for reviewing and deciding whether to advance the bill.
Current stage: in_committee.
Floor Vote.
Summary
Key Facts
- The bill is titled the 'Byron Nash Renal Medullary Carcinoma Awareness Act of 2023'.
- The bill is classified as an HR (House of Representatives) bill.
- The bill has been referred to the House Committee on Energy and Commerce for consideration.
Frequently Asked Questions
What is the current status of this bill?
What is Renal Medullary Carcinoma?
Why It Matters
The bill initiates the legislative process to potentially allocate federal resources or mandate public health initiatives specifically targeting Renal Medullary Carcinoma awareness.
News Coverage
Sponsors
Discoveries
Patterns POLISCOPE noticed across the record. These are observations to investigate, not conclusions.
Rare Cancer Focus
The bill represents a targeted legislative effort to address a specific, rare form of cancer through federal awareness initiatives.
Connected Entities
Analysis Score
0–100- Significance30How much this matters to a regular citizen
- Controversy10Intensity of disagreement among stakeholders
- Entertainment5Compellingness for a non-policy-wonk reader
- Buzz15Current news / social attention level
Publisher tools